Evidence map›Paper›PMID 40366550›Full record

ArticleMolecular diversity2026

Discovery and optimization of novel indolecarboxylic acid derivative as potent glucagon-like peptide‑1 receptor agonists.

Wanting Zhao, Yuqian Yin, Zhuo Shi, Ke Yang, Xinglin Li, Yushe Yang, Tongfei Jing, Zhenghui Kang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Novel Small Molecule GLP-1R Agonists Based on 1Molecules (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wanting ZhaoSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Yuqian YinSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Zhuo ShiSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Ke YangZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China.
Xinglin LiZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China.
Yushe YangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Tongfei JingZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China. jingtongfei0379@zidd.ac.cn.
Zhenghui KangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. kangzhenghui@simm.ac.cn.

Funding

China Postdoctoral Science Foundation under Grant 2023M743925Financial support from Natural Science Foundation of Guangdong Province 2023A1515110403Financial support from Natural Science Foundation of Guangdong Province 2024A1515030037
6 · The paper itself

Abstract

Several glucagon-like peptide-1 receptor (GLP-1R) agonists have been recognized as effective therapeutic strategies for T2DM and obesity. Our efforts focused on modifying the pyridine fragment and the region near the benzo[d]imidazole moiety of danuglipron to reduce the inhibitory activity on the hERG channel while preserving its ability to activate GLP-1R, leading to the synthesis of 21 novel derivatives. An optimized indolecarboxylic acid derivative, YK-11 (EC

Indexed as

Drug DiscoveryGlucagon-Like Peptide-1 Receptor AgonistsIndolesERG1 Potassium ChannelGlucagon-Like Peptide-1 ReceptorHumansMolecular Docking SimulationStructure-Activity RelationshipERG1 Potassium ChannelGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsIndolesAgonistsGLP-1RhERGIndolecarboxylic acid derivativeObesityT2DM

Identifiers

PMID40366550

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.